Cabaletta Bio Receives Orphan Drug Status for CABA-201
Company Announcements

Cabaletta Bio Receives Orphan Drug Status for CABA-201

The latest update is out from Cabaletta Bio (CABA).

Cabaletta Bio, Inc. has announced a significant milestone as the U.S. FDA awarded Orphan Drug Designation to their innovative CAR T cell therapy, CABA-201, aimed at treating systemic sclerosis. This designation could potentially enhance the therapy’s development and approval process, offering new hope for patients with this rare autoimmune disease. Investors may view this update as a positive step for Cabaletta Bio’s growth in the biotechnology market.

Learn more about CABA stock on TipRanks’ Stock Analysis page.

Related Articles
GlobeNewswireCabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyKyverna, Cabaletta selloffs an overreaction, says Wells Fargo
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!